Printer Friendly

HYGEIA PHARMACEUTICALS COMPLETES DEVELOPMENT OF MONOPHARM-CSA

 SAN DIEGO, Dec. 8 /PRNewswire/ -- HYGEIA Pharmaceuticals Inc. (Vancouver: HYG) today announced the completion of the conceptual development of Monopharm-CSA, a serum tumor marker for adenocarcinoma, based on the AgSK1 system. Preliminary results using genetically engineered AgSK1 for assay development indicate that approximately 50 percent of the samples tested (representing a 90 percent confidence level) were positive for the Monopharm-C antigen. HYGEIA scientists are also using the genetically engineered AgSK1 for cancer vaccine development. HYGEIA is actively seeking a partner to commercialize and market this diagnostic indicator.
 The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
 -0- 12/8/93
 /CONTACT: John Reynolds, 800-345-0498 or 602-443-4900/
 (HYG.)


CO: HYGEIA Pharmaceuticals Inc. ST: California IN: MTC SU:

MF-JL -- SD005 -- 1973 12/08/93 18:05 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 8, 1993
Words:136
Previous Article:CALLAWAY GOLF COMPANY SIGNS FOUR-YEAR ENDORSEMENT AGREEMENT WITH PGA CHAMPION PAUL AZINGER
Next Article:LEVI STRAUSS & CO. ANNOUNCES NEW EXECUTIVE APPOINTMENTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters